- Meditech company OncoSil is in the final stages of landing an important CE Mark certification
- A CE approval would let OncoSil sell its namesake cancer treatment in Europe
- The treatment is a medical implant designed to augment radiation treatment for pancreatic and liver cancer
- OncoSil shares have dipped 9.52 per cent today at midday trade, valued at 19 cents each
Click here for the entire article on The Market Herald
OncoSil Medical is one step closer to CE Mark certification in Europe
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
0.030(3.09%) |
Mkt cap ! $14.22M | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.00 | 96.0¢ | $39.65K | 40.44K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 96.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 391 | 2 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |